French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases
Methodological detailsnational recommendations, two systematic literature reviews (2005-2024), multidisciplinary task force, expert consensus with multiple voting rounds, Multidisciplinary task force: rheumatologists, oncologists, pulmonologists, gynecologists and patient representatives
- National recommendations
- Two systematic literature reviews (2005-2024)
- Multidisciplinary task force
- Expert consensus with multiple voting rounds
- Multidisciplinary task force: rheumatologists, oncologists, pulmonologists, gynecologists and patient representatives
Recommendations
As issued by the authors
Apply general population cancer screening programs, adapted to immunocompromised patients with chronic inflammatory rheumatic diseases (CIRDs); may involve earlier and/or more frequent screening
Systematic risk assessment before initiating therapies
Reinforced preventive strategies such as HPV vaccination and smoking cessation
At least one dermatologic evaluation during follow-up
Decisions on higher-risk therapies, such as JAK inhibitors and abatacept, should involve multidisciplinary discussions
Original publication
French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases. Joint Bone Spine. Published 12 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →